AstraZeneca (AZN +0.8%) ticks higher after presenting final overall survival analysis on...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca (AZN +0.8%) ticks higher after presenting final overall survival analysis on Faslodex, which showed a 4.1 month difference in median overall survival when using Faslodex Injection 500 mg compared with 250 mg. Faslodex is a treatment for metastatic breast cancer in postmenopausal women. The findings were presented today at the 35th CTRC-AACR San Antonio Breast Cancer Symposium.